Ispire Reports Q1 FY2025 Loss as US Market Sales Drop by $8.1 Million

Nov.12.2024
Ispire Reports Q1 FY2025 Loss as US Market Sales Drop by $8.1 Million
Ispire (NASDAQ: ISPR) reports Q1 fiscal results, citing a revenue drop due to US market sales decline.

Ispire Technology (Nasdaq: ISPR) announced its financial results for the first quarter of fiscal year 2025 on November 11, 2024, covering the period ending September 30, 2024. 

 

The company reported a year-over-year revenue decrease of 8.2% to $39.3 million, a gross profit increase of 13.2% to $7.7 million, and a net loss that widened by 330.8% to $5.6 million.

 

Ispire announced that its decrease in revenue was mainly due to a decline in product sales in the US market, which dropped from $17.8 million in the previous period to $9.7 million in the current period, a decrease of $8.1 million. 

 

However, this was partially offset by increased sales of e-cigarette products in the European market and elsewhere. Sales in the European market increased by $2.1 million (from $19.9 million to $22 million), while sales in other regions increased by $3.7 million (from $60,000 to $3.8 million), with the main increase coming from sales in the South African market, which rose by $2.9 million.

 

In this quarter, total operating expenses increased by 67.5% to $12.9 million compared to the same period last year. Aspire attributed the rise in operating expenses to a $700,000 increase in marketing activities, a $1 million increase in stock compensation for sales personnel, and a $100,000 increase in employee salaries and wages at Aspire Science. 

 

Additionally, the company incurred an extra $1 million in stock compensation expenses in the three months ending September 30, 2024, to incentivize management, employees, and service providers. The company also set aside an additional $1.9 million in bad debt expenses as a provision for credit losses on accounts receivable.

 

As of September 30, 2024, Ispire had $37.7 million in cash and cash equivalents, and $16.6 million in operating capital.

 

"We are pleased to expand into the Middle East, North Africa, and the global duty-free market through a milestone five-year exclusive distribution agreement with ANDS. This partnership will allow us to introduce the Hidden Hills Club product line to new markets, offering consumers innovative, harm-reduced alternatives," Inspire's Co-CEO Michael Wang said.

 

"Our performance in the first quarter of our 2025 fiscal year met internal expectations, as we adjusted our US market strategy and also faced some delays in shipments. Despite these obstacles, our financial performance in the first quarter remained strong, with gross profit increasing by 13.2% year-on-year, and gross margin rising from 16.0% in the first quarter of the 2024 fiscal year to 19.5% in the 2025 fiscal year," Ispire's Chief Financial Officer Jim McCormick said.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philippine FDA Requires Licenses for Vape Products with Medical Claims
Philippine FDA Requires Licenses for Vape Products with Medical Claims
The Philippine Food and Drug Administration has announced that establishments selling vaporized nicotine and non-nicotine products and novel tobacco products with medicinal or therapeutic claims must secure Licenses to Operate. Such products are also required to be registered as pharmaceutical products through the Center for Drug Regulation and Research. The FDA urged stakeholders to comply with the new requirements to ensure product safety, efficacy and quality.
Dec.22 by 2FIRSTS.ai
JUUL Files ITC Complaint over Vaporizer Device Infringement
JUUL Files ITC Complaint over Vaporizer Device Infringement
The U.S. International Trade Commission has instituted a Section 337 investigation following a complaint filed by JUUL Labs, Inc. and VMR Products LLC. The complaint alleges that certain vaporizer devices, cartridges and related components infringe two U.S. patents. The investigation covers importation, sale for importation and post-importation sales in the United States, with the complainants seeking a limited exclusion order and cease and desist orders.
Dec.19 by 2FIRSTS.ai
British Museum Ends Long-Running Sponsorship with Japan Tobacco International
British Museum Ends Long-Running Sponsorship with Japan Tobacco International
According to The Guardian, the British Museum has ended its 15-year sponsorship with Japan Tobacco International after government inquiries into whether the deal breached WHO tobacco-control rules. Critics had long opposed the partnership, while the museum said sponsorship remains essential for its financial stability and public access.
Nov.20
South Korea Formalizes Harmful Substance Controls for Cigarettes and E-cigarettes
South Korea Formalizes Harmful Substance Controls for Cigarettes and E-cigarettes
South Korea’s Ministry of Food and Drug Safety has issued a notice establishing testing items and methods for harmful substances in tobacco products, including cigarettes and e-cigarettes.
Dec.18 by 2FIRSTS.ai
Thailand to Establish Inter-Agency Committee to Strengthen E-Cigarette Enforcement
Thailand to Establish Inter-Agency Committee to Strengthen E-Cigarette Enforcement
The Thai government will establish an inter-agency committee under the Prime Minister’s Office to address the rapid spread of e-cigarettes among youth. Deputy Prime Minister Sophon Sarum said the fragmented enforcement across multiple laws and agencies has created gaps. The new mechanism will coordinate enforcement, report directly to the Cabinet, and propose legal amendments if current laws are insufficient.
Nov.20 by 2FIRSTS.ai
PMI Extends Ferrari Partnership to 2026, Bringing ZYN Nicotine Pouches to F1
PMI Extends Ferrari Partnership to 2026, Bringing ZYN Nicotine Pouches to F1
Philip Morris International (PMI) has announced that it will extend its partnerships with Scuderia Ferrari HP and the Ferrari Challenge through the 2026 season and beyond, with its smoke-free nicotine pouch brand ZYN set to appear on Ferrari’s F1 livery for the first time from the 2025 Abu Dhabi Grand Prix. The company estimates that, as of June 30, 2025, more than 41 million adult consumers were using its smoke-free products worldwide.
Dec.04 by 2FIRSTS.ai